Phase II, Multicenter, Open-label, Clinical Trial of Trabectedin (Yondelis) in Metastatic Breast Cancer Patients With Triple Negative Profile (ER-, PR-, HER2-), HER2 Overexpressing Tumors and BRCA1 or BRCA2 Mutation Carriers.

Trial Profile

Phase II, Multicenter, Open-label, Clinical Trial of Trabectedin (Yondelis) in Metastatic Breast Cancer Patients With Triple Negative Profile (ER-, PR-, HER2-), HER2 Overexpressing Tumors and BRCA1 or BRCA2 Mutation Carriers.

Completed
Phase of Trial: Phase II

Latest Information Update: 22 Apr 2014

At a glance

  • Drugs Trabectedin (Primary) ; Dexamethasone; Dexamethasone
  • Indications Advanced breast cancer
  • Focus Pharmacogenomic; Registrational; Therapeutic Use
  • Sponsors Janssen Research & Development
  • Most Recent Events

    • 27 Dec 2012 Planned End Date changed from 1 Jun 2007 to 1 Jul 2011 as reported by ClinicalTrials.gov.
    • 29 Dec 2011 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
    • 12 May 2011 Planned end date added (Jun 2007) reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top